Clinical trial
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine…
NCT00227773 · Eastern Cooperative Oncology Group, Other · Withdrawn
Key facts
| NCT number | NCT00227773 |
|---|---|
| Title | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors |
| Official title | Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma |
| Intervention type | Drug, Procedure |
| Interventions | octreotide acetate, vatalanib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, endocrine therapy, enzyme inhibitor therapy, growth factor antagonist therapy, hormone therapy, protein tyrosine kinase inhibitor therapy and 1 more |
| Enrollment | 0 |
| First posted | Sep 28, 2005 |
| Last update posted | Oct 8, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: